Table of Content

1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency


2. Research Methodology
2.1. Research Process
2.2. Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research
2.3. Market Assessment
2.3.1. Market Size Estimation
2.3.1.1. Bottom-Up Approach
2.3.1.2. Top-Down Approach
2.3.1.3. Growth Forecast
2.3.2. Market Share Analysis
2.4. Assumptions for the Study
2.5. Limitations for the Study


3. Executive Summary


4. Market Insights
4.1. Market Overview
4.2. Drivers
4.2.1. Growing Burden of Chronic and Infectious Diseases
4.2.2. Rising Focus Towards Personalized Healthcare
4.2.3. Delays in Drug Development and the Subsequent Increase in Development Costs
4.2.4. Shift Towards Value-Based Care
4.2.5. Rapidly Growing Big Data in Healthcare
4.3. Restraints
4.3.1. Reluctance to Rely on Real-World Studies
4.4. Opportunities
4.4.1. Rising Focus on End-to-End RWE Services
4.4.2. Rising Adoption of Wearable Devices and Artificial Intelligence in RWE
4.5. Challenges
4.5.1. Lack of Standardized Methodologies to Develop RWE
4.6. Key Market Trends
4.6.1. Growing Adoption of RWE in Drug Development and Commercialization
4.6.2. Rising Number of Consolidations
4.6.3. Improved Patient Outcomes and Value Creation from Real-World Evidence
4.7. Impact Assessment of COVID-19 on the U.S. RWE Solutions Market


5. Regulatory Analysis – U.S. Real-World Evidence (RWE) Solutions Market


6. Pricing Models (EMR/Genomic/Integrated Datasets)
6.1. Introduction
6.2. Pay Per Patient Record (Volume-Based Pricing)
6.3. Pay Per Usage (Value-Based Pricing)
6.4. Annual Subscription


7. U.S. Real-World Evidence Solutions Market, by Component
7.1. Introduction
7.2. Datasets
7.2.1. Disparate Datasets
7.2.1.1. EMR/EHR/Clinical Data
7.2.1.2. Claims & Billing Data
7.2.1.3. Pharmacy Data
7.2.1.4. Product/Disease Registries Data
7.2.1.5. Other Disparate Datasets
7.2.2. Integrated Datasets
7.3. Consulting & Analytics


8. U.S. Real-World Evidence Solutions Market, by Application
8.1. Introduction
8.2. Market Access & Reimbursement/Coverage Decisions
8.3. Drug Development & Approvals
8.3.1. Oncology
8.3.2. Neurology
8.3.3. Immunology
8.3.4. Cardiovascular Diseases
8.3.5. Other Therapeutic Areas
8.4. Medical Device Development & Approvals
8.5. Post-Market Surveillance
8.6. Other Applications


9. U.S. Real-World Evidence Solutions Market, by End User
9.1. Introduction
9.2. Pharmaceutical, Biotechnology, and Medical Device Companies
9.3. Healthcare Payers
9.4. Healthcare Providers
9.5. Other End Users


10. Competitive Landscape
10.1. Introduction
10.2. Key Growth Strategies
10.3. Competitive Benchmarking
10.4. Market Share Analysis (2020)
10.4.1. IQVIA Holdings, Inc. (U.S.)
10.4.2. ICON plc (Ireland)
10.4.3. PPD, Inc. (U.S.)


11. Company Profiles (Business Overview, Financial Overview, Solution Portfolio, Strategic Developments)
11.1. Anthem, Inc.
11.2. Clinigen Group plc.
11.3. Cognizant Technology Solutions Corporation
11.4. ICON plc
11.5. IQVIA HOLDINGS INC.
11.6. Oracle Corporation
11.7. PAREXEL International Corporation
11.8. PerkinElmer, Inc.
11.9. PPD, Inc.
11.10. SAS Institute Inc.
11.11. UnitedHealth Group Incorporated
11.12. Flatiron Health, Inc.



List of Figures

List of Figures

Figure 1 Key Stakeholders
Figure 2 Research Process
Figure 3 Key Secondary Sources
Figure 4 Primary Research Techniques
Figure 5 Key Executives Interviewed
Figure 6 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
Figure 7 Market Size Estimation
Figure 8 U.S. Real-World Evidence Solutions Market, by Component, 2022 Vs. 2029 (USD Million)
Figure 9 U.S. Real-World Evidence Solutions Market, by Application, 2022 Vs. 2029 (USD Million)
Figure 10 U.S. Real-World Evidence Solutions Market, by End User, 2022 Vs. 2029 (USD Million)
Figure 11 Market Dynamics
Figure 12 Number of People in the U.S. With Chronic Conditions (2000–2030)
Figure 13 Percentage of Personalized Medicines Approved (2015-2020)
Figure 14 U.S. Real-World Evidence Solutions Market Size, by Component, 2022–2029 (USD Million)
Figure 15 U.S.: Number of E-Prescriptions, 2013–2020 (Billions)
Figure 16 U.S. Real-World Evidence Solutions Market Size, by Application, 2022–2029 (USD Million)
Figure 17 Dalys of Neurological Disorders in the U.S., 2010–2021 (In Thousands)
Figure 18 U.S.: Hepatitis A Virus (HAV) Infections, 2013–2020
Figure 19 U.S. Real-World Evidence Solutions Market Size, by End User, 2022–2029 (USD Million)
Figure 20 U.S. Pharmaceutical R&D Spending, 1980–2019 (USD Billion)
Figure 21 Key Growth Strategies Adopted by Leading Players (2018–2022)
Figure 22 U.S. Real-World Evidence Solutions: Competitive Benchmarking
Figure 23 Market Share Analysis: U.S. Real-World Evidence Solutions Industry (2021)
Figure 24 Anthem, Inc.: Financial Overview (2021)
Figure 25 Clinigen Group plc: Financial Overview (2021)
Figure 26 Cognizant Technology Solutions Corporation: Financial Overview (2021)
Figure 27 ICON plc: Financial Overview (2021)
Figure 28 IQVIA HOLDINGS INC.: Financial Overview (2021)
Figure 29 Oracle Corporation: Financial Overview (2021)
Figure 30 PerkinElmer, Inc.: Financial Overview (2022)
Figure 31 PPD, Inc.: Financial Overview (2020)
Figure 32 SAS Institute Inc.: Financial Overview (2021)
Figure 33 UnitedHealth Group Incorporated.: Financial Overview (2021)

List of Tables

List of Tables

Table 1 U.S. Real-World Evidence Solutions Market Drivers: Impact Analysis (2022-2029)
Table 2 Total Per-Study Cost (In Usd Million), by Phase and Therapeutic Area
Table 3 Sources of Healthcare Data
Table 4 U.S. Real-World Evidence Solutions Market Restraints: Impact Analysis (2022-2029)
Table 5 Observed Indicative Prices of Real-World Data by Type (USD Per Patient Record)
Table 6 U.S. Real-World Evidence Solutions Market Size, by Component, 2012–2029 (USD Million)
Table 7 U.S. Real-World Evidence Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 8 U.S. RWE Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 9 U.S. Real-World Evidence Solutions Market Size, by Application, 2020–2029 (USD Million)
Table 10 U.S. RWE Solutions Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 11 Estimated Number of New Cancer Cases in the U.S. (2019–2023)
Table 12 Medical Costs Associated With Cardiovascular Diseases (2010-2030) (USD Billion)
Table 13 Other Therapeutic Areas: Drugs in the R&D Pipeline
Table 14 U.S. RWE Solutions Market Size, by End User, 2020–2029 (USD Million)
Table 15 Recent Developments, by Company, 2018–2022